Ladarixin, an inhibitor of IL-8 receptors CXCR1 and CXCR2, in new onset T1D a multicenter,randomized, double-blind, placebo-controlled trial
19/05/2022
Autori: Lorenzo Piemonti, Bart Keymeulen, Pieter Gillard, Thomas Linn, Emanuele Bosi, Ludger Rose, Paolo Pozzilli, Francesco Giorgino, Efisio Cossu, Luisa Daffonchio, Giovanni Goisis, Pier Adelchi Ruffini, Anna Rita Maurizi, Flavio Mantelli, Marcello Allegretti
Pubblicato in:
"DOM (Diabetes, Obesity and Metabolism)"